TISSIUM

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management.

TISSIUM headquartered in Europe, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $25.2B in funding across 120 round(s). With a team of 101-250 employees, TISSIUM is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - TISSIUM, raised $11.0M. Discover more about their projects, partnerships, and impact on our platform.